Pharvaris N.V.PHVSNASDAQ
Loading
R&D Expense Growth Recovery in ProgressRecovering
Percentile Rank43
3Y CAGR-6.2%
5Y CAGR-7.6%
Year-over-Year Change

Year-over-year research & development expense growth

3Y CAGR
-6.2%/yr
Annual compound
5Y CAGR
-7.6%/yr
Consistent
Percentile
P43
Within normal range
vs 5Y Ago
0.7x
Contraction
Streak
1 yr
Consecutive growthRecovering
PeriodValue
202450.31%
202314.29%
202260.32%
202160.93%
2020249.53%
201974.53%
20180.00%
20170.00%